- About Us
- Our Research
- Our Research Streams
- Cancer Research
- Clinical Sciences
- Population & Health Services Research
- Injury & Rehabilitation
- Mental Health
- Scientific Publications
- Our Awards
- Our Facilities
- Hit the Fairways for Prostate Cancer Research
- Kick a Goal for Prostate Cancer and Support the ‘Best of the Blues’ State of Origin Charity Event
- Vital New Clues to Accelerate Oesophageal Cancer Treatment
- When Does Surgery Have No Benefit?
- Annie Walsh shoots for the stars in medical research
- Focus on PhD Student Lauren Bell
- Need for equal access to global radiation therapy services put in the spotlight
- Nicholas chooses his pathway and is fulfilling his dreams
- Putting Diabetic Foot Disease on the health agenda
- Radiation oncologist Mei Ling Yap shares her story
- Stephen Skegg honours his Father - NGINA Golf Day 2016
- Story of a young researcher who followed his pathway to greatness.
- Window to Hope gives new light to people with TBI
- MRI-Linac Program
- Our Research Streams
- News and Media
- Friends of The Institute
- How You Can Help
Thomas Ashworth CTC Symposium
Thursday 7th August 2014 Hilton Hotel, Sydney
The Inaugural Thomas Ashworth Symposium will bring together medical researchers and clinicians to advance the science and clinical utility of circulating tumour cell (CTC) and circulating tumour nucleic acid (ctNA) research.
This one day symposium (9am - 5pm) is a unique opportunity to foster growth of the Australian CTC research community. The symposium pays tribute to the Australian physician Thomas Ashworth who first oberved circulating tumor cells in 1869.
The Thomas Ashworth CTC Symposium will be open to researchers and clinicians who have an interest in the identification, isolation and characterisation of CTCs and ctNA.
The meeting will explore the latest developments in CTC enumeration, ctNA and molecular characterisation including techniques for cellular, molecular and immunological analyses, next generation sequencing and culture of CTCs. Specific focus will be on the clinical utility of CTCs and ctNA, including the prospects and current limitations how these biomarkers can aid the rational decision making in cancer therapy.
Kevin Spring, Organising Chair, Thomas Ashworth CTC Symposium